Full Papers
Gastrointestinal dysmotility complicating Behçet’s syndrome: description of a newly recognised clinical phenotype
D.P. Kidd1, H. Kibrom2, E. Ssendi3, M. Hall4, F. Fortune5
- The National Behçet’s Syndrome Centre of Excellence, Royal London Hospital, Whitechapel, London, UK. desmond.kidd@nhs.net
- Apheresis Unit, Department of Haematology, Royal Free Hospital, London, UK.
- The National Behçet’s Syndrome Centre of Excellence, Royal London Hospital, Whitechapel, London, UK.
- Department of Nuclear Medicine, Royal Free Hospital, London, UK.
- The National Behçet’s Syndrome Centre of Excellence, Royal London Hospital, Whitechapel, London, UK.
CER16940
2023 Vol.41, N°10
PI 2087, PF 2092
Full Papers
Free to view
(click on article PDF icon to read the article)
PMID: 37902272 [PubMed]
Received: 23/06/2023
Accepted : 18/09/2023
In Press: 30/10/2023
Published: 30/10/2023
Abstract
OBJECTIVES:
Gastrointestinal dysmotility may arise in a variety of auto-immune and auto-inflammatory diseases and hitherto has not been described in Behçet’s syndrome (BS).
METHODS:
We present data on a cohort of seven patients under our care who presented with symptoms of and investigations compatible with an immune associated disorder of gastrointestinal motility, or enteric neuropathy.
RESULTS:
We describe the clinical features and investigation results. We undertook a trial of a novel treatment in the disease, apheresis, and noted a response not only to the enteric neuropathy but also to the systemic features of the disease, despite previous maximal immunosuppressive therapy in most cases.
CONCLUSIONS:
Gastrointestinal dysmotility may arise in BS and is effectively treated by apheresis. The mechanism by which this response is made immunologically requires to be elucidated in future studies.
